Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 16/20 | 0.75 |
| ▸ | CA1 | P00915 | 15/20 | 0.75 |
| ▸ | CA2 | P00918 | 15/20 | 0.75 |
| ▸ | CA12 | O43570 | 6/20 | 0.71 |
| ▸ | USP2 | O75604 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALPL | P05186 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | ALPG | P10696 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12231957 | 0.92 | CA9 (0.72) | CA9CA1CA2CA12USP2 | |
| SCHEMBL15828111 | 0.92 | CA9 (0.83) | CA9CA1CA2CA12USP2 | |
| SCHEMBL13971293 | 0.92 | USP2 (0.72) | CA9CA1CA2CA12USP2 | |
| SCHEMBL412012 | 0.90 | CA9 (0.78) | CA9CA1CA2CA12USP2 | |
| SCHEMBL29699213 | 0.90 | CA9 (0.78) | CA9CA1CA2CA12USP2 | |
| SCHEMBL19954964 | 0.90 | CA9 (0.72) | CA9CA1CA2CA12USP2 | |
| SCHEMBL2234764 | 0.90 | CA9 (0.83) | CA9CA1CA2CA12USP2 | |
| SCHEMBL13097493 | 0.89 | CA9 (0.75) | CA9CA1CA2CA12USP2 | |
| SCHEMBL15355564 | 0.88 | USP2 (0.75) | CA9CA1CA2CA12USP2 | |
| SCHEMBL14073670 | 0.88 | CA9 (0.69) | CA9CA1CA2CA12USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995110-B2 | Trehalose analogues | CENTRAL MICHIGAN UNIVERSITY (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200115408-A1 | TREHALOSE ANALOGUES | CENTRAL MICHIGAN UNIVERSITY | 2020-04-16 | — | — | US | disclosed |
| US-20200054676-A1 | Targeted Ligand-Payload Based Drug Delivery for Cell Therapy | PURDUE RESEARCH FOUNDATION | 2020-02-20 | — | — | US | disclosed |
| US-20170252460-A1 | FUNCTIONALIZING NANOFIBRES | BOVIN NICOLAI (RU) | 2017-09-07 | — | — | US | disclosed |
| EP-2391714-B1 | METHODS FOR LIGATION AND USES THEREOF | WHITEHEAD INST BIOMEDICAL RES (US) | 2017-04-05 | — | — | EP | disclosed |
| US-8940501-B2 | Methods for ligation and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-01-27 | — | — | US | disclosed |
| US-8513023-B2 | Prognostic method | NORGINE BV (NL) | 2013-08-20 | — | — | US | disclosed |
| US-20110321183-A1 | METHODS FOR LIGATION AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2009132310-A1 | INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE THWART MYCOBACTERIAL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2008022355-A2 | METHODS AND REAGENTS FOR DETECTING PHOSPHOMONOESTER GROUPS | PERKINELMER LAS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070221884-A1 | Liminescent Silicon Oxide Flakes | CIBA SPECIALTY CHEMICALS CORP. | 2007-09-27 | — | — | US | disclosed |
| US-20070048640-A1 | Photoreceptor layer having rhodamine additive | XEROX CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115408-A1 | TREHALOSE ANALOGUES | TREH, TALDO1, GALE | CA9 1512/4885CA1 2754/4885CA2 3388/4885 |
| US-20170252460-A1 | FUNCTIONALIZING NANOFIBRES | BTD, ILK, WASF2 | CA9 3735/4885CA1 2666/4885CA2 4082/4885 |
| US-10995110-B2 | Trehalose analogues | TREH, TALDO1, GALE | CA9 1512/4885CA1 2754/4885CA2 3388/4885 |
| US-20200054676-A1 | Targeted Ligand-Payload Based Drug Delivery for Cell Therapy | HAVCR2, BST2, CD74 | CA9 4204/4885CA1 3676/4885CA2 4526/4885 |
| US-20110321183-A1 | METHODS FOR LIGATION AND USES THEREOF | ACOT7, LYPLA1, ACSL3 | CA9 1483/4885CA1 2809/4885CA2 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.